A Phase 3 interventional study of Atorvastatin and Placebo to Atorvastatin in Hyperlipidemia, sponsored by Amgen. Completed at 58 sites in 13 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-11-29.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing evolocumab in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. evolocumab · Hyperlipidemias.
Among the 21 studies testing evolocumab in Hyperlipidemias, this one is the 6th largest by enrollment, is one of 7 that started in 2013, is one of 12 in phase 3, and was the 11th registered.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →None of the 21 studies testing evolocumab in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 7 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 511 is above the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 307 across the 21 interventional studies. Of the 20 that completed or were terminated, 19 (95%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 21 have an industry lead sponsor. The 6 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
17 studies in Hyperlipidemias by Amgen: none open now, none under way, none of them phase 3. Of 17 finished, 17 (100%) have results posted.
Among the 17 studies in Hyperlipidemias by Amgen, this one is the 6th largest by enrollment, is one of 7 that started in 2013, is one of 11 in phase 3, and was the 11th registered.
Amgen’s Hyperlipidemias studies by the year they started, since 2010.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing evolocumab in Hyperlipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 17 in Hyperlipidemias:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study was to evaluate the effect of 24 weeks of evolocumab administered subcutaneously (SC) every month, compared with ezetimibe, on low-density lipoprotein cholesterol (LDL-C) levels in adults with high cholesterol who are unable to tolerate an effective dose of a statin due to muscle-related side effects (MRSE).
The study is divided into 3 parts (A, B, C). After an initial 4-week washout period in which any statins, ezetimibe, or other lipid-lowering agents were discontinued, participants were enrolled in phase A, a double-blind, placebo-controlled crossover procedure to rechallenge patients with atorvastatin. Patients were randomly assigned in a 1:1 ratio to receive either atorvastatin (20 mg daily) or matching placebo for the first 10 weeks (period 1), then underwent a 2-week washout period, followed by crossover to the alternate therapy for a second 10-week period (period 2). Patients who experienced intolerable muscle symptoms during the first period did not complete the full 10 weeks of exposure but entered a 2-week washout period before proceeding to period 2.
Participants who did not develop muscle-related side effects were removed from the study, as were patients who reported muscle-related side effects during a placebo period.
After completion of phase A, patients who experienced muscle-related adverse effects while taking atorvastatin but not placebo were eligible for phase B, a 24-week, double-blind randomization to ezetimibe or evolocumab using a double-dummy design in which patients received either injectable placebo and oral ezetimibe or injectable evolocumab and oral placebo. A patient could proceed directly to phase B if they had a documented history of creatine kinase (CK) elevation more than 10 times the upper limit of normal accompanied by muscle symptoms while taking statin therapy, with documented resolution of both CK elevation and symptoms upon discontinuation of statin therapy.
These study procedures were designed to ensure that only patients with reproducible statin-associated muscle symptoms entered phase B of the study. For phase B, participants were randomized 2:1 to receive subcutaneously administered evolocumab (420 mg monthly) or oral ezetimibe (10 mg daily). Randomization in part B was stratified by screening LDL-C level (\< 180 mg/dL [4.66 mmol/L] vs. ≥ 180 mg/dL) at study baseline.
Participants who completed phase B and did not discontinue SC investigational product for any reason, including an adverse event, were eligible to proceed to the 2-year open-label extension phase C to evaluate the long-term safety and efficacy of evolocumab in statin-intolerant patients. Participants in phase C were allowed to choose quarterly between evolocumab 420 mg SC QM or evolocumab 140 mg SC every 2 weeks (Q2W).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received atorvastatin 20 mg orally for 10 weeks (period 1) followed by placebo orally for 10 weeks (period 2), separated by a 2-week washout period.
Drug: Atorvastatin · Drug: Placebo to Atorvastatin
Participants received placebo orally for 10 weeks (period 1) followed by atorvastatin 20 mg orally for 10 weeks (period 2), separated by a 2-week washout period.
Drug: Atorvastatin · Drug: Placebo to Atorvastatin
Participants received 10 mg ezetimibe orally only a day and placebo to evolocumab by subcutaneous injection once a month for 24 weeks.
Drug: Ezetimibe · Other: Placebo to Evolocumab
Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo to ezetimibe orally once a day for 24 weeks.
Other: Placebo to Ezetimibe · Drug: Evolocumab
Participants who completed part B and were eligible to proceed to open-label extension part C and could choose quarterly between evolocumab 420 mg once a month or evolocumab 140 mg every 2 weeks for up to 2 years.
Drug: Evolocumab
Atorvastatin was supplied as over-encapsulated 20 mg tablets
Also known as: Lipitor
Placebo matching to atorvastatin supplied as over-encapsulated tablets
Placebo matching to Ezetimibe supplied as over-encapsulated tablets.
Ezetimibe was supplied as 10 mg tablets, over-encapsulated for blinding.
Also known as: Zetia
Placebo matching to evolocumab supplied as single-use prefilled autoinjector/pen(s)
Evolocumab supplied as single-use prefilled autoinjector/pen(s)
Also known as: Repatha
Percent Change From Baseline in LDL-C at the Mean of Weeks 22 and 24
Time frame: Baseline and weeks 22 and 24
Percent Change From Baseline in LDL-C at Week 24
Time frame: Baseline and week 24
Change From Baseline in LDL-C at the Mean of Weeks 22 and 24
Time frame: Baselie and weeks 22 and 24
Change From Baseline in LDL-C at Week 24
Time frame: Baseline and week 24
Percentage of Participants Who Achieved a Mean LDL-C at Weeks 22 and 24 of Less Than 70 mg/dL
Time frame: Weeks 22 and 24
Percentage of Participants Who Achieved LDL-C at Week 24 of Less Than 70 mg/dL
Time frame: Week 24
Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 22 and 24
Time frame: Baseline and weeks 22 and 24
Percent Change From Baseline in Total Cholesterol at Week 24
Time frame: Baseline and week 24
Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 22 and 24
Time frame: Baseline and weeks 22 and 24
Percent Change From Baseline in Non-HDL-C at Week 24
Time frame: Baseline and week 24
Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 22 and 24
Time frame: Baseline and weeks 22 and 24
Percent Change From Baseline in Apolipoprotein B at Week 24
Time frame: Baseline and week 24
Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at the Mean of Weeks 22 and 24
Time frame: Baseline and weeks 22 and 24
Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 24
Time frame: Baseline and week 24
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 22 and 24
Time frame: Baseline and Weeks 22 and 24
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 24
Time frame: Baseline and week 24
Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 22 and 24
Time frame: Baseline and Weeks 22 and 24
Percent Change From Baseline in Lipoprotein(a) at Week 24
Time frame: Baseline and week 24
Percent Change From Baseline in Triglycerides at the Mean of Weeks 22 and 24
Time frame: Baseline and weeks 22 and 24
Percent Change From Baseline in Triglycerides at Week 24
Time frame: Baseline and week 24
Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 24
Time frame: Baseline and weeks 22 and 24
Percent Change From Baseline in HDL-C at Week 24
Time frame: Baseline and week 24
Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 22 and 24
Time frame: Baseline and weeks 22 and 24
Percent Change From Baseline in VLDL-C at Week 24
Time frame: Baseline and week 24
A total of 511 participants were enrolled (492 in Part A and 19 directly in Part B) at 53 centers in the United States of America, Europe, Australia, New Zealand, Canada, and South Africa from December 2013 to November 2014. Results are reported for participants randomized in Part B. Part C was ongoing at the time of this analysis.
| Milestone | Ezetimibe | Evolocumab |
|---|---|---|
| Started | 73 | 145 |
| Completed | 70 | 138 |
| Not completed | 3 | 7 |
| Withdrew: Withdrawal by subject | 3 | 5 |
| Withdrew: Sponsor decision | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| percent change | Ezetimibe | Evolocumab |
|---|---|---|
| Percent Change From Baseline in LDL-C at the Mean of Weeks 22 and 24 | -16.70 ± 1.91 | -54.50 ± 1.39 |
| percent change | Ezetimibe | Evolocumab |
|---|---|---|
| Percent Change From Baseline in LDL-C at Week 24 | -16.69 ± 2.11 | -52.76 ± 1.52 |
| mg/dL | Ezetimibe | Evolocumab |
|---|---|---|
| Change From Baseline in LDL-C at the Mean of Weeks 22 and 24 | -31.0 ± 3.8 | -106.8 ± 2.7 |
| mg/dL | Ezetimibe | Evolocumab |
|---|---|---|
| Change From Baseline in LDL-C at Week 24 | -31.2 ± 4.0 | -102.9 ± 2.9 |
| percentage of participants | Ezetimibe | Evolocumab |
|---|---|---|
| Percentage of Participants Who Achieved a Mean LDL-C at Weeks 22 and 24 of Less Than 70 mg/dL | 1.4 (0.3 to 7.7) | 29.9 (22.9 to 38.1) |
| percentage of participants | Ezetimibe | Evolocumab |
|---|---|---|
| Percentage of Participants Who Achieved LDL-C at Week 24 of Less Than 70 mg/dL | 0.0 (0.0 to 6.3) | 27.4 (20.1 to 36.1) |
| percent change | Ezetimibe | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 22 and 24 | -11.43 ± 1.41 | -38.04 ± 1.03 |
| percent change | Ezetimibe | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol at Week 24 | -11.57 ± 1.52 | -36.64 ± 1.10 |
| percent change | Ezetimibe | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 22 and 24 | -14.38 ± 1.72 | -47.44 ± 1.25 |
| percent change | Ezetimibe | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 24 | -14.62 ± 1.83 | -45.72 ± 1.32 |
| percent change | Ezetimibe | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 22 and 24 | -11.42 ± 1.82 | -45.28 ± 1.31 |
| percent change | Ezetimibe | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein B at Week 24 | -11.74 ± 1.94 | -43.50 ± 1.40 |
| percent change | Ezetimibe | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at the Mean of Weeks 22 and 24 | -11.48 ± 1.75 | -41.39 ± 1.27 |
| percent change | Ezetimibe | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 24 | -12.84 ± 1.85 | -40.04 ± 1.33 |
| percent change | Ezetimibe | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 22 and 24 | -11.86 ± 1.89 | -45.99 ± 1.36 |
| percent change | Ezetimibe | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 24 | -12.62 ± 1.97 | -44.60 ± 1.41 |
| percent change | Ezetimibe | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 22 and 24 | -1.63 ± 2.80 | -22.71 ± 2.03 |
| percent change | Ezetimibe | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Lipoprotein(a) at Week 24 | 0.17 ± 3.05 | -21.06 ± 2.19 |
| percent change | Ezetimibe | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Triglycerides at the Mean of Weeks 22 and 24 | -0.95 ± 3.94 | -5.39 ± 2.84 |
| percent change | Ezetimibe | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Triglycerides at Week 24 | -1.07 ± 4.97 | -2.88 ± 3.54 |
| percent change | Ezetimibe | Evolocumab |
|---|---|---|
| Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 24 | 1.66 ± 1.71 | 7.85 ± 1.24 |
| percent change | Ezetimibe | Evolocumab |
|---|---|---|
| Percent Change From Baseline in HDL-C at Week 24 | 2.90 ± 1.89 | 7.40 ± 1.36 |
| percent change | Ezetimibe | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 22 and 24 | -2.15 ± 3.22 | -6.81 ± 2.33 |
| percent change | Ezetimibe | Evolocumab |
|---|---|---|
| Percent Change From Baseline in VLDL-C at Week 24 | -2.66 ± 3.88 | -3.90 ± 2.78 |
Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Evolocumab | — | 9/145 (6.2%) | 80/145 (55.2%) |
| Ezetimibe | — | 10/73 (13.7%) | 40/73 (54.8%) |
| Event | Evolocumab | Ezetimibe |
|---|---|---|
| Angina pectorisCardiac disorders | 1/145 | 2/73 |
| Atrial fibrillationCardiac disorders | 2/145 | 0/73 |
| Acute myocardial infarctionCardiac disorders | 0/145 | 1/73 |
| Angina unstableCardiac disorders | 0/145 | 1/73 |
| Gastrointestinal angiodysplasiaGastrointestinal disorders | 0/145 | 1/73 |
| Urinary tract infectionInfections and infestations | 0/145 | 1/73 |
| Hip fractureInjury, poisoning and procedural complications | 0/145 | 1/73 |
| Back painMusculoskeletal and connective tissue disorders | 0/145 | 1/73 |
| Carotid artery stenosisNervous system disorders | 0/145 | 1/73 |
| NeuralgiaNervous system disorders | 0/145 | 1/73 |
| Event | Evolocumab | Ezetimibe |
|---|---|---|
| MyalgiaMusculoskeletal and connective tissue disorders | 20/145 | 16/73 |
| NasopharyngitisInfections and infestations | 14/145 | 2/73 |
| HeadacheNervous system disorders | 10/145 | 7/73 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 13/145 | 1/73 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 13/145 | 5/73 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 13/145 | 1/73 |
| FatigueGeneral disorders | 12/145 | 5/73 |
| Back painMusculoskeletal and connective tissue disorders | 10/145 | 5/73 |
| ConstipationGastrointestinal disorders | 3/145 | 4/73 |
| DiarrhoeaGastrointestinal disorders | 6/145 | 4/73 |
| Age, Continuous(years) | Ezetimibe | Evolocumab | Total |
|---|---|---|---|
| Mean | 58.5 ± 9.4 | 59.0 ± 11.1 | 58.8 ± 10.5 |
| Age, Customized(Participants) | Ezetimibe | Evolocumab | Total |
|---|---|---|---|
| < 65 years | 52 | 92 | 144 |
| ≥ 65 years | 21 | 53 | 74 |
| Sex: Female, Male(Participants) | Ezetimibe | Evolocumab | Total |
|---|---|---|---|
| Female | 39 | 67 | 106 |
| Male | 34 | 78 | 112 |
| Ethnicity (NIH/OMB)(Participants) | Ezetimibe | Evolocumab | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 |
| Not Hispanic or Latino | 73 | 143 | 216 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Ezetimibe | Evolocumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 2 | 3 |
| Black or African American | 3 | 3 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| White | 69 | 138 | 207 |
| Other | 0 | 2 | 2 |
| Stratification Factor: Screening Low-density Lipoprotein Cholesterol (LDL-C)(Participants) | Ezetimibe | Evolocumab | Total |
|---|---|---|---|
| < 180 mg/dL | 21 | 40 | 61 |
| ≥ 180 mg/dL | 52 | 105 | 157 |
| LDL-C Concentation(mg/dL) | Ezetimibe | Evolocumab | Total |
|---|---|---|---|
| Mean | 221.9 ± 70.2 | 218.8 ± 73.1 | 219.9 ± 72.0 |
| Total Cholesterol Concentration(mg/dL) | Ezetimibe | Evolocumab | Total |
|---|---|---|---|
| Mean | 308.0 ± 73.8 | 306.5 ± 75.4 | 307.0 ± 74.7 |
8 further baseline measures are reported on the registry.
Ran from Dec 2013 to primary completion in Nov 2015, 23 months.
Results were first posted in Mar 2018, 2 years 4 months after primary completion. A results delay was requested in Sep 2016.
Of 51 industry-sponsored phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 23 months is above that.
Counting every sponsor, half of 57 studies reached it within 18 months; a quarter within 11 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab